US EditionExclusive: Neuro startup Leal raises $30M Series A for schizophrenia and ALS trials
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Exclusive: Neuro startup Leal raises $30M Series A for schizophrenia and ALS trials
The brain-focused startup Leal Therapeutics has raised a modest Series A round to push its lead neurology drugs deeper into the clinic, its CEO exclusively told Endpoints News. CEO Asa Abeliovich, a former Columbia University ...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
